Jefferson University Hospitals

Provider Profile

Steven J. Cohen, MD

Steven J. Cohen, MD

Academic Title: Professor
Chief, Medical Oncology and Hematology Division, Abington Hospital
Vice-Chair, Department of Medical Oncology, Sidney Kimmel Cancer Center at Jefferson

Specialties
Medical Oncology
Medical Oncology - Colorectal Cancer
Medical Oncology - Esophageal Cancer
Medical Oncology - Gastrointestinal (GI) Cancer
Medical Oncology - Liver Cancer
Medical Oncology - Pancreatic Cancer
Medical Oncology - Stomach Cancer

Make An Appointment

Click to call 1-800-JEFF-NOW (800-533-3669) or

Office Locations

Abington
1200 Old York Road
1 Widener - AMH
Abington PA 19001
Phone: (215) 481-2400
Fax: (215) 481-7438
Philadelphia
925 Chestnut Street
Suite 320A
Philadelphia PA 19107
Phone: (215) 955-8874
Fax: (215) 955-2340

Medical Services

Board Certifications

  • Medical Oncology

Hospital Affiliation / Admitting Privileges

  • Thomas Jefferson University Hospital
  • Abington Hospital

Awards and Honors

NCI Clinical Investigator Team Leadership Award

ASCO Leadership Development Program Graduate

Education

  • SUNY at Stony Brook School of Medicine, Medical School

Internship

  • Temple University Hospital

Residency

  • Temple University Hospital

Fellowship

  • Fox Chase Cancer Center

Jefferson physicians accept most health insurance plans, including those listed below. However, plan acceptance may vary by practice and may be subject to change. If you have questions about whether a specific physician accepts your insurance, please contact your insurance company.

Insurances Accepted

  • Aetna PA Employee Benefit Trust Fund (PEBTF)
  • Consumer Health Network PPO
  • Employers Health Network PPO
  • Health Management Network PPO
  • Keystone First VIP Choice
  • Mercy LIFE
  • PlanCare America
  • Prime Health Services, Inc.
  • UPMC HMO,PPO ReadingHspEmpONLY
  • UPMC Medicare HMO

Recent Publications

Predictors of Hematologic Toxicity and Chemotherapy Dose Intensity in Patients Undergoing Chemoradiation for Pancreatic Cancer

A Phase 2 Randomized, Double-Blind, Multicenter Trial of Imexon Plus Gemcitabine Versus Gemcitabine Plus Placebo in Patients with Metastatic Chemotherapy-naïve Pancreatic Adenocarcinoma

Phase I/II trial of labetuzumab govitecan (Anti-CEACAM5/ SN-38 Antibody-Drug Conjugate) in patients with refractory or relapsing metastatic colorectal cancer

Molecular Profiling in Colon Cancer: Where Are We Now?

Cytotoxic therapy in advanced pancreatic cancer: Where we are and where we are headed

Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer

Baseline hemoglobin and liver function predict tolerability and overall survival of patients receiving radioembolization for chemotherapy-refractory metastatic colorectal cancer

Hepatopulmonary shunting: A prognostic indicator of survival in patients with metastatic colorectal adenocarcinoma treated with90Y radioembolization

Front-line treatment of metastatic colorectal cancer

Neoadjuvant therapy for rectal cancer affects lymph node yield and status without clear implications on outcome: The case for eliminating a metric and using preoperative staging to guide therapy

Risk of radiation pneumonitis in patients receiving taxane-based trimodality therapy for locally advanced esophageal cancer

Chemotherapy use and adoption of new agents is affected by age and comorbidities in patients with metastatic colorectal cancer

Prognostic Significance of MUC-1 in Circulating Tumor Cells in Patients with Metastatic Pancreatic Adenocarcinoma

Molecular profiling of neuroendocrine malignancies to identify prognostic and therapeutic markers: A Fox Chase Cancer Center Pilot Study

CALGB 80403 (Alliance)/E1206: A randomized phase II study of three chemotherapy regimens plus cetuximab in metastatic esophageal and gastroesophageal Junction Cancers

Dosimetric predictors of hematologic toxicity in patients undergoing concurrent gemcitabine-based chemoradiation for localized pancreatic cancer

Erratum: A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer Ann Oncol 2015; 26: 1923-1929 doi: 10.1093/annonc/mdv264

Safety and efficacy of radioembolization in elderly (≥ 70 years) and younger patients with unresectable liver-dominant colorectal cancer

A phase 1b study of erlotinib in combination with gemcitabine and nab-paclitaxel in patients with previously untreated advanced pancreatic cancer: An Academic Oncology GI Cancer Consortium study

Phase II study of olaparib (AZD-2281) after standard systemic therapies for disseminated colorectal cancer